Cardiology | Home | MIMS Malaysia

Cardiology

Does the use of revascularization along with medical therapy improve CAD outcomes?

Yesterday

While there may be no particular survival benefit to performing revascularization on top of medical therapy, the combination does seem to reduce the risk of poor outcomes, such as fatal myocardial infarction and unplanned revascularizations and stroke, recent meta-analysis reports.

Standing good for heart health

Jairia Dela Cruz, Yesterday

Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.

Flavonoid-rich diet reduces risk of peripheral artery disease hospitalizations

Stephen Padilla, 2 days ago

Consumption of a diet rich in flavonoids, found in almost all fruits and vegetables, can lower the risk of hospitalization for peripheral artery disease (PAD), revascularizations or endovascular surgery, and lower extremity amputations, according to a study.

Intermittent fasting improves cardiometabolic health in MetS patients

3 days ago

Intermittent fasting (IF) appears to reduce cardiometabolic risk factors through the alteration of the gut microbial community and functional pathways in metabolic syndrome (MetS) patients, results of a recent study have shown.

Insulin clearance may be vascular damage indicator

3 days ago

Among people at risk of type 2 diabetes mellitus (T2DM), lowered insulin clearance may be an early indicator of vascular damage independently of other classical cardiovascular disease (CVD) risk factors, a recent study reports.

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Empagliflozin: Another SGLT-2i in HFrEF armamentarium

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

Empagliflozin advancing on all fronts: Readying for the future with EMPEROR

11 Aug 2020

In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

HK in CKD: Do diet, HD frequency matter?

Elvira Manzano, 28 Jun 2020

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.

Polypill + aspirin TIPped as CVD primary prevention strategy

Roshini Claire Anthony, 14 Jan 2021

A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.

SCOPE II: New self-expanding bioprosthetic valve fails to demo noninferiority to existing option

Roshini Claire Anthony, 26 Dec 2020

The novel self-expanding bioprosthetic ACURATE neo valve did not demonstrate noninferiority to the currently available CoreValve Evolute valve in patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), according to the SCOPE* II trial.

High-dose flu vaccine no better than standard-dose in reducing death, CV hospitalization

Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.

Rilonacept shows therapeutic potential for recurrent pericarditis

Audrey Abella, 21 Dec 2020

In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.

Obesity portends worse outcomes in COVID-19, even for young adults

Pearl Toh, 18 Dec 2020

Obesity, particularly the severe class, was associated with an increased risk of mechanical ventilation and death in patients hospitalized with COVID-19 — a risk that is even more profound among the younger age group, reveals data from the AHA COVID-19 CVD registry*.

Omecamtiv mecarbil: New player in HF treatment?

Audrey Abella, 18 Dec 2020

Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.

AFFIRM-AHF: IV iron cuts risk of HF readmissions

Pearl Toh, 15 Dec 2020

Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!